Commentary: Effect of Angiotensin-Converting-Enzyme Inhibitor and Angiotensin II Receptor Antagonist Treatment on ACE2 Expression and SARS-CoV-2 Replication in Primary Airway Epithelial Cells.
作者信息
Simko Fedor, Baka Tomas
机构信息
Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
3rd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
出版信息
Front Pharmacol. 2022 Jan 28;13:842512. doi: 10.3389/fphar.2022.842512. eCollection 2022.
Abstract
摘要
相似文献
1
Commentary: Effect of Angiotensin-Converting-Enzyme Inhibitor and Angiotensin II Receptor Antagonist Treatment on ACE2 Expression and SARS-CoV-2 Replication in Primary Airway Epithelial Cells.
Front Pharmacol. 2022 Jan 28;13:842512. doi: 10.3389/fphar.2022.842512. eCollection 2022.
2
Effect of Angiotensin-Converting-Enzyme Inhibitor and Angiotensin II Receptor Antagonist Treatment on ACE2 Expression and SARS-CoV-2 Replication in Primary Airway Epithelial Cells.
Front Pharmacol. 2021 Nov 19;12:765951. doi: 10.3389/fphar.2021.765951. eCollection 2021.
3
A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice.
FASEB J. 2021 Mar;35(3):e21419. doi: 10.1096/fj.202100016R.
4
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat?
Clin Sci (Lond). 2021 Apr 30;135(8):1009-1014. doi: 10.1042/CS20210182.
5
Angiotensin II Receptor Blockers (ARBs Antihypertensive Agents) Increase Replication of SARS-CoV-2 in Vero E6 Cells.
Front Cell Infect Microbiol. 2021 Jun 11;11:639177. doi: 10.3389/fcimb.2021.639177. eCollection 2021.
6
Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.
J Am Coll Cardiol. 2020 Jun 23;75(24):3085-3095. doi: 10.1016/j.jacc.2020.04.028. Epub 2020 Apr 16.
7
Dysregulation of ACE (Angiotensin-Converting Enzyme)-2 and Renin-Angiotensin Peptides in SARS-CoV-2 Mediated Mortality and End-Organ Injuries.
Hypertension. 2022 Feb;79(2):365-378. doi: 10.1161/HYPERTENSIONAHA.121.18295. Epub 2021 Nov 30.
8
The pivotal link between ACE2 deficiency and SARS-CoV-2 infection.
Eur J Intern Med. 2020 Jun;76:14-20. doi: 10.1016/j.ejim.2020.04.037. Epub 2020 Apr 20.
9
Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Front Immunol. 2021 Dec 22;12:732690. doi: 10.3389/fimmu.2021.732690. eCollection 2021.
10
ACE2: from protection of liver disease to propagation of COVID-19.
Clin Sci (Lond). 2020 Dec 11;134(23):3137-3158. doi: 10.1042/CS20201268.
引用本文的文献
1
The effect of zofenopril on the cardiovascular system of spontaneously hypertensive rats treated with the ACE2 inhibitor MLN-4760.
Biol Res. 2023 Oct 25;56(1):55. doi: 10.1186/s40659-023-00466-x.
2
Mechanisms of Cardiovascular System Injury Induced by COVID-19 in Elderly Patients With Cardiovascular History.
Front Cardiovasc Med. 2022 May 4;9:859505. doi: 10.3389/fcvm.2022.859505. eCollection 2022.
本文引用的文献
1
Effect of Angiotensin-Converting-Enzyme Inhibitor and Angiotensin II Receptor Antagonist Treatment on ACE2 Expression and SARS-CoV-2 Replication in Primary Airway Epithelial Cells.
Front Pharmacol. 2021 Nov 19;12:765951. doi: 10.3389/fphar.2021.765951. eCollection 2021.
2
A low aldosterone/renin ratio and high soluble ACE2 associate with COVID-19 severity.
J Hypertens. 2022 Mar 1;40(3):606-614. doi: 10.1097/HJH.0000000000003054.
3
Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial.
EClinicalMedicine. 2021 Nov;41:101152. doi: 10.1016/j.eclinm.2021.101152. Epub 2021 Oct 24.
4
Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo.
Cell Discov. 2021 Aug 12;7(1):65. doi: 10.1038/s41421-021-00302-0.
5
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat?
Clin Sci (Lond). 2021 Apr 30;135(8):1009-1014. doi: 10.1042/CS20210182.
6
Angiotensin Receptor Blockers for COVID-19: Pathophysiological and Pharmacological Considerations About Ongoing and Future Prospective Clinical Trials.
Front Pharmacol. 2021 Mar 29;12:603736. doi: 10.3389/fphar.2021.603736. eCollection 2021.
7
Renin-Angiotensin-Aldosterone System: Friend or Foe-The Matter of Balance. Insight on History, Therapeutic Implications and COVID-19 Interactions.
Int J Mol Sci. 2021 Mar 22;22(6):3217. doi: 10.3390/ijms22063217.
8
Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin-Kallikrein System in Severe COVID-19.
Viruses. 2021 Feb 16;13(2):309. doi: 10.3390/v13020309.
9
Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19.
Clin Sci (Lond). 2021 Feb 12;135(3):465-481. doi: 10.1042/CS20201511.
10
The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins.
PLoS Biol. 2020 Dec 21;18(12):e3001016. doi: 10.1371/journal.pbio.3001016. eCollection 2020 Dec.
Zotero 插件